AFP and gastric cancer: These results suggested the potential importance of AFP as a predictive biomarker for cisplatin response in gastric cancer and suggest that AFP-silencing may enhance the efficacy of cisplatin-based chemotherapy in AFP-expressing gastric cancer patients.